TenSixty Bio develops novel cancer treatments by integrating biology, machine learning, and technology development. The company focuses on translating advanced research into actionable therapeutic candidates. Their work aims to create new treatment modalities through data-driven experimentation.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatments often lack precision, leading to off-target effects and limited efficacy. Identifying novel and specific targets on cancer cells remains a challenge, hindering the development of more effective and targeted therapies. Existing approaches may not fully leverage the potential of high-throughput technologies and machine learning for target discovery.
Solution
TenSixty BioSciences is developing a platform that integrates machine learning and high-throughput technologies to identify novel antibody targets on cancer cells. By focusing on a biology-first approach, the platform aims to create a comprehensive atlas of antibody targets on the surface of cancer cells. This enables the discovery of new, precise cancer targets and the development of improved therapeutics with enhanced specificity. The company's approach seeks to address the limitations of current cancer treatments by transforming these novel targets into effective, life-saving drugs.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel cancer therapeutics.
Features
- Utilizes machine learning algorithms to analyze complex biological data and identify potential antibody targets.
- Employs high-throughput screening technologies to rapidly assess a large number of potential targets.
- Focuses on cell-based models to ensure identified targets are relevant in a biological context.
- Creates an atlas of antibody targets on cancer cells, providing a resource for drug development.